Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00255151

Recruitment Status : Completed

First Posted : November 17, 2005

Results First Posted : August 28, 2009

Last Update Posted : February 3, 2012

Sponsor:

Information provided by (Responsible Party):

Takeda

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Triple (Participant, Investigator, Outcomes Assessor); Primary Purpose: Treatment
Conditions:	Esophagitis, Reflux Esophagitis, Peptic
Interventions:	Drug: Dexlansoprazole MR Drug: Placebo

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects were enrolled at 105 sites in the United States; date of first dose (04 January 2006; date of last procedure: 14 November 2006).

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Subjects had to have endoscopically proven healed erosive esophagitis (EE) after 4 to 8 weeks of treatment with lansoprazole 30 mg once-daily (QD), dexlansoprazole modified release (MR) 60 mg QD, or dexlansoprazole MR 90 mg QD in the EE healing studies, T-EE04-084 (NCT00251693) and T-EE04-085 (NCT00251719).

Reporting Groups

	Description
Placebo QD	Placebo capsules, orally, once daily for up to 6 months.
Dexlansoprazole MR 60 mg QD	Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 6 months.
Dexlansoprazole MR 90 mg QD	Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 6 months.

Participant Flow: Overall Study

	Placebo QD	Dexlansoprazole MR 60 mg QD	Dexlansoprazole MR 90 mg QD
STARTED	140	159	152
COMPLETED	17	110	103
NOT COMPLETED	123	49	49
Adverse Event	10	6	9
Lost to Follow-up	4	3	4
Withdrawal by Subject	18	17	8
Noncompliance	0	1	2
Subject Request/Subject Unavailable	1	1	2
Relapse of Erosive Esophagitis	78	16	12
Possible Barrett's Esophagus	1	3	8
Esophageal Stricture	0	0	1
Therapeutic Failure	11	2	3

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Placebo QD	Placebo capsules, orally, once daily for up to 6 months.
Dexlansoprazole MR 60 mg QD	Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 6 months.
Dexlansoprazole MR 90 mg QD	Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 6 months.
Total	Total of all reporting groups

Baseline Measures

Placebo QD

Dexlansoprazole MR 60 mg QD

Dexlansoprazole MR 90 mg QD

Total

Overall Participants Analyzed
[Units: Participants]

140

159

152

451

Age
[Units: Years]
Mean (Standard Deviation)

48.2 (12.88)

49.7 (12.66)

48.8 (13.76)

48.9 (13.09)

Age, Customized
[Units: Participants]

<45 years

159

45 to <65 years

248

≥65 years

Gender
[Units: Participants]

Female

216

Male

235

Race (NIH/OMB)
[Units: Participants]

American Indian or Alaska Native

Asian

Native Hawaiian or Other Pacific Islander

Black or African American

White

124

135

136

395

More than one race

Unknown or Not Reported

Ethnicity (NIH/OMB)
[Units: Participants]

Hispanic or Latino

Not Hispanic or Latino

125

140

138

403

Unknown or Not Reported

Baseline Los Angeles (LA) Classification Grade for Erosive Esophagitis (EE) ^[1]
[Units: Participants]

A: ≥1 mucosal break <5 mm

172

B: ≥1 mucosal break ≥5 mm

167

C: ≥1 mucosal break <75% of circumference

D: ≥1 mucosal break ≥75% of circumference

^[1]	Baseline values from Studies T-EE04-084 (NCT00251693)and T-EE04-085 (NCT00251719), with severity of EE increasing from Grade A to Grade D.

Outcome Measures

Show All Outcome Measures

1. Primary:

Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis. [ Time Frame: 6 months ]

Show Outcome Measure 1

2. Primary:

Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Life Table Method [ Time Frame: 6 months ]

Show Outcome Measure 2

3. Secondary:

Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Median. [ Time Frame: 6 months ]

Show Outcome Measure 3

4. Secondary:

Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Mean. [ Time Frame: 6 months ]

Show Outcome Measure 4

5. Secondary:

Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Median. [ Time Frame: 6 months ]

Show Outcome Measure 5

6. Secondary:

Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Mean. [ Time Frame: 6 months ]

Show Outcome Measure 6

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.

Results Point of Contact:

Name/Title: Sr. VP Clinical Sciences
Organization: Takeda Global Research and Development Center, Inc.
phone: 800-778-2860
e-mail: clinicaltrialregistry@tpna.com

Publications of Results:

Howden CW, Larsen LM, Perez MC, Palmer R, Atkinson SN. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. Aliment Pharmacol Ther. 2009 Nov 1;30(9):895-907. doi: 10.1111/j.1365-2036.2009.04119.x. Epub 2009 Aug 14.

Responsible Party:	Takeda
ClinicalTrials.gov Identifier:	NCT00255151 History of Changes
Other Study ID Numbers:	T-EE04-087 U1111-1114-1767 ( Registry Identifier: WHO )
First Submitted:	November 15, 2005
First Posted:	November 17, 2005
Results First Submitted:	February 20, 2009
Results First Posted:	August 28, 2009
Last Update Posted:	February 3, 2012

To Top